March 2009 Volume 27 Number 3, pp 209 - 296
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=58&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=32&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=38&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=4&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Harvard Business School Executive Education
Tomorrow's leaders are innovating through today's recession. Are you one of them?
Clayton Christensen contends that breakthrough innovations often come
when tension is greatest and resources are most limited. We invite you
to read his interview (http://links.ealert.nature.com/ctt?kn=56&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0 with
The Wall Street Journal and learn more about HBS's science-business programs.
http://links.ealert.nature.com/ctt?kn=108&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
miRCURY LNA(TM) PCR
Your fast track to microRNA discovery
The success of our LNA-based microRNA
real-time PCR products continues.
The secret? See how we compare to other leading brands, here
http://links.ealert.nature.com/ctt?kn=46&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
We now have more than 600 assays - learn more now.
http://links.ealert.nature.com/ctt?kn=57&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
JOHNS HOPKINS UNIVERSITY
MASTER OF SCIENCE IN BIOINFORMATICS
Earn your MASTER'S degree FULLY ONLINE or ONSITE
from a leader in science research and engineering.
ONLINE INFO SESSION - MARCH 4
Learn more and RSVP online at http://links.ealert.nature.com/ctt?kn=14&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
A new mechanism for Alzheimer's?
Genentech scientists have proposed a new mechanism for Alzheimer's disease pathogenesis in a recent Nature paper and have identified a trio of new AD targets. Will this work lead to a major change of focus in developing drugs for the disease?
Find out more by reading the first indepth analysis of the scientific and commercial potential of the work in SciBX: Science-Business eXchange.
http://links.ealert.nature.com/ctt?kn=91&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
A balancing act p209
Contrary to Genentech's claims, turning over all in vitro diagnostics to the US Food and Drug Administration (FDA) is the wrong approach to achieve better clinical validation of tests.
doi:10.1038/nbt0309-209
http://links.ealert.nature.com/ctt?kn=61&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
NEWS
----------------------
Comparative effectiveness casts first shadows across US industry pp211 - 212
Emily Waltz
doi:10.1038/nbt0309-211
http://links.ealert.nature.com/ctt?kn=87&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Genentech grapples with direct offer p212
Brady Huggett
doi:10.1038/nbt0309-212
http://links.ealert.nature.com/ctt?kn=129&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Geron gets green light for human trial of ES cell-derived product pp213 - 214
Joe Alper
doi:10.1038/nbt0309-213a
http://links.ealert.nature.com/ctt?kn=22&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Alnylam dealt blow p213
Asher Mullard
doi:10.1038/nbt0309-213b
http://links.ealert.nature.com/ctt?kn=77&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
C-Path sets diagnostics standard p213
Jim Roberts
doi:10.1038/nbt0309-213c
http://links.ealert.nature.com/ctt?kn=119&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Vatican cheers GM p214
Anna Meldolesi
doi:10.1038/nbt0309-214a
http://links.ealert.nature.com/ctt?kn=124&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
China overhauls patent law p214
Jane Qiu
doi:10.1038/nbt0309-214b
http://links.ealert.nature.com/ctt?kn=96&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Report blames NICE for hastening decline of UK biotech pp215 - 217
Nuala Moran
doi:10.1038/nbt0309-215
http://links.ealert.nature.com/ctt?kn=109&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Norway's swift bail out p216
Nayanah Siva
doi:10.1038/nbt0309-216a
http://links.ealert.nature.com/ctt?kn=106&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Green fuels thrust p216
Victor Bethencourt
doi:10.1038/nbt0309-216b
http://links.ealert.nature.com/ctt?kn=121&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Pfizer swallows Wyeth, validates niche buster pp218 - 219
Cormac Sheridan
doi:10.1038/nbt0309-218
http://links.ealert.nature.com/ctt?kn=48&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
PROFILE
Willem 'Pim' Stemmer p220
One of the most pioneering protein engineers of his generation is also a serial entrepreneur with a flair for spotting new business opportunities.
Crispin Littlehales
doi:10.1038/nbt0309-220
http://links.ealert.nature.com/ctt?kn=34&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
DATA PAGE
13.3 million farmers cultivate GM crops p221
Andrew Marshall
doi:10.1038/nbt0309-221
http://links.ealert.nature.com/ctt?kn=85&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
NEWS FEATURE
Fresh from the biologic pipeline pp222 - 225
Randy Osborne reports on the latest product approvals.
Randall Osborne
doi:10.1038/nbt0309-222
http://links.ealert.nature.com/ctt?kn=69&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Webinar: Monoclonal Antibody Analysis and QC, Martin A. Winkler, Ph.D.
Dr. Winkler, formerly, Principal Scientist, Abbott, gives this webinar at
http://links.ealert.nature.com/ctt?kn=98&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Topics include: FDA requirements, Purity and Concentration, IEF, CE-IEF, Mass Spectrometry Western blotting, RIPA, Binding constants, Carbohydrate determination, and Trouble-shooting MAbs.
====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
When times get tough
With the major economies around the world in recession, what strategic actions should you be taking?
Simcha Jong
doi:10.1038/bioe.2009.1
http://links.ealert.nature.com/ctt?kn=63&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
A survey of South-North health biotech collaboration pp229 - 232
Christina C. Melon et al.
doi:10.1038/nbt0309-229
http://links.ealert.nature.com/ctt?kn=76&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
BIO and the next generation p232
Jim Greenwood
doi:10.1038/nbt0309-232
http://links.ealert.nature.com/ctt?kn=83&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Bonsai biotech p233
William Bains
doi:10.1038/nbt0309-233
http://links.ealert.nature.com/ctt?kn=125&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
COMMENTARY
Proliferation-resistant biotechnology: an approach to improve biological security pp234 - 236
Is there a way to design DNA synthesis technology with safeguards that prevent its cooption for nefarious purposes?
Ali Nouri and Christopher F Chyba
doi:10.1038/nbt0309-234
http://links.ealert.nature.com/ctt?kn=127&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
FEATURES
----------------------
Biotech under Barack pp237 - 244
The Obama administration looks to be a welcome shot in the arm for the scientific endeavor, but the current economic crisis is likely to keep several issues of key interest to biotech firmly on the back burner.
Jeffrey L Fox
doi:10.1038/nbt0309-237
http://links.ealert.nature.com/ctt?kn=20&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
PATENTS
Bilski blundering biotech pp245 - 248
Is the Federal Circuit's decision in In re: Bilski yet a further restraint on patenting biotech and pharmaceutical inventions?
William J Simmons
doi:10.1038/nbt0309-245
http://links.ealert.nature.com/ctt?kn=37&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Recent patent applications in RNA interference p249
doi:10.1038/nbt0309-249
http://links.ealert.nature.com/ctt?kn=50&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
A splicing component adapted to gene silencing pp250 - 251
U1 adaptors offer an alternative to siRNA for targeted gene knockdown.
Xavier Roca and Adrian R Krainer
doi:10.1038/nbt0309-250
http://links.ealert.nature.com/ctt?kn=18&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Jump-starting cancer gene discovery pp251 - 252
Targeting transposon mutagenesis to a specific tissue facilitates screening for tumor-associated genes and tracking of tumor lineages.
Anthony Uren and Anton Berns
doi:10.1038/nbt0309-251
http://links.ealert.nature.com/ctt?kn=68&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Combinatorial stem cell mobilization pp252 - 253
Different subsets of bone marrow stem cells can be mobilized by varying drug treatments.
Mikhail G Kolonin and Paul J Simmons
doi:10.1038/nbt0309-252
http://links.ealert.nature.com/ctt?kn=54&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Research highlights p254
doi:10.1038/nbt0309-254
http://links.ealert.nature.com/ctt?kn=131&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PRIMER
Maximizing power in association studies pp255 - 256
Only a subset of genetic variants can be examined in genome-wide surveys for genetic risk factors. How can a fixed set of markers account for the entire genome by acting as proxies for neighboring associations?
Eran Halperin and Dietrich A Stephan
doi:10.1038/nbt0309-255
http://links.ealert.nature.com/ctt?kn=70&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ARTICLES
Gene silencing by synthetic U1 Adaptors pp257 - 263
Rafal Goraczniak, Mark A Behlke and Samuel I Gunderson
doi:10.1038/nbt.1525
Abstract: http://links.ealert.nature.com/ctt?kn=72&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=10&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma pp264 - 274
Vincent W Keng et al.
doi:10.1038/nbt.1526
Abstract: http://links.ealert.nature.com/ctt?kn=65&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=35&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
LETTERS
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling pp275 - 280
Stuart M Chambers et al.
doi:10.1038/nbt.1529
Abstract: http://links.ealert.nature.com/ctt?kn=31&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=12&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells pp281 - 287
Barak Blum, Ori Bar-Nur, Tamar Golan-Lev and Nissim Benvenisty
doi:10.1038/nbt.1527
Abstract: http://links.ealert.nature.com/ctt?kn=23&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=3&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Autocatalytic aptazymes enable ligand-dependent exponential amplification of RNA pp288 - 292
Bianca J Lam and Gerald F Joyce
doi:10.1038/nbt.1528
Abstract: http://links.ealert.nature.com/ctt?kn=92&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=75&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Biotech scientists bank on big pharma's biologics push pp293 - 295
Biologics represent a new hope for big pharma and new dreams for biotech scientists.
Grace Wong
doi:10.1038/nbt0309-293
http://links.ealert.nature.com/ctt?kn=90&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
PEOPLE
People p296
doi:10.1038/nbt0309-296
http://links.ealert.nature.com/ctt?kn=122&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Genetics and Genomics of Infectious Diseases 2009
March 21-24, 2009
Ritz Carlton Millenia, Singapore
This conference will engage basic and clinical scientists, including human geneticists, genome scientists, computational biologists, and experts in pathogenic microbial agents to chart the effects of genomics on questions in global infectious disease management.
For more information and to register visit:
http://links.ealert.nature.com/ctt?kn=111&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=19&m=31882285&r=MTc3MTg2NzE2NgS2&b=2&j=NDY0MTY1MTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
